Table 1.
Patient characteristics at each tumor regression grade
| TRG1 | TRG2 | TRG3 | P | |
|---|---|---|---|---|
| Number | ||||
| 42 (33%) | 56 (44%) | 29 (23%) | ||
| Age at surgery | 0.6208 | |||
| 65 (45–75) | 63 (41–75) | 64 (44–77) | ||
| Sex | 0.7033 | |||
| Female | 5 (12%) | 10 (18%) | 5 (17%) | |
| Male | 37 (88%) | 46 (82%) | 24 (83%) | |
| Tumor location | 0.9615 | |||
| Upper | 9 (21%) | 12 (22%) | 5 (17%) | |
| Middle | 20 (48%) | 27 (48%) | 13 (45%) | |
| Lower | 13 (31%) | 17 (30%) | 11 (38%) | |
| Depth of invasion (cT) | 0.5727 | |||
| T1 | 1 (2%) | 2 (4%) | 2 (7%) | |
| T2 | 1 (2%) | 4 (7%) | 3 (10%) | |
| T3 | 40 (95%) | 48 (86%) | 23 (79%) | |
| T4 | 0 (0%) | 2 (4%) | 1 (4%) | |
| Lymph node metastasis (cN) | 0.9545 | |||
| N0 | 4 (10%) | 4 (7%) | 3 (10%) | |
| N1 | 24 (57%) | 33 (59%) | 19 (66%) | |
| N2 | 13 (31%) | 18 (32%) | 7 (24%) | |
| N3 | 1 (2%) | 1 (2%) | 0 (0%) | |
| Clinical stage (cStage) | 0.8519 | |||
| IIA | 4 (10%) | 4 (7%) | 3 (10%) | |
| IIB | 2 (5%) | 6 (11%) | 5 (17%) | |
| IIIA | 22 (52%) | 26 (47%) | 13 (45%) | |
| IIIB | 13 (31%) | 17 (30%) | 7 (24%) | |
| IIIC | 1 (2%) | 3 (5%) | 1 (4%) | |
| Tumor differentiation | 0.1977 | |||
| Not poorly | 38 (90%) | 49 (88%) | 22 (76%) | |
| Poorly | 4 (10%) | 7 (12%) | 7 (24%) | |
| Tumor stage after NACRT | < 0.0001* | |||
| Downstaged | 16 (38%) | 30 (54%) | 28 (97%) | |
| No change | 21 (50%) | 19 (34%) | 1 (3%) | |
| Upstaged | 5 (12%) | 7 (13%) | 0 (0%) | |
| Recurrence | 0.0113* | |||
| Presence | 22 (52%) | 22 (39%) | 5 (17%) | |
| Absence | 20 (48%) | 34 (61%) | 24 (83%) | |
| Prognosis | 0.0316* | |||
| Alive | 22 (52%) | 37 (66%) | 25 (86%) | |
| Dead with ESCC | 18 (43%) | 15 (27%) | 3 (10%) | |
| Dead with other diseases | 2 (5%) | 4 (7%) | 1 (4%) | |
TRG, tumor regression grade; *, Considered significant